CleanIngredients
Menu

FDA warning letters and supplement ingredient testing: our count, 2021 to 2026

Published by CleanIngredients, publish date pending. Data pulled 15 November 2026 from FDA's public warning letters table. Not legal or regulatory advice.

Of 58 FDA warning letters citing 21 CFR Part 111 from January 2021 to November 2026, 41 cited section 111.75. 41 of 58 (70.7%) cite 21 CFR 111.75. We read the full text of every non-tobacco FDA warning letter in FDA's public table, 2,595 letters issued from January 2021 to 3 November 2026. Of the 58 that cite the dietary supplement CGMP rule (21 CFR Part 111), 41 cite section 111.75, the rule on determining whether ingredient and product specifications are met. Method, data, and limits are below.

Key numbers

Why we counted this

CleanIngredients is a free public-evidence directory for US supplement brands comparing plant-extract manufacturers in China. Our scores describe how much public documentation a supplier has shown, not product safety, and we do not independently test suppliers. FDA's rules for US finished-supplement makers are one reason brands ask suppliers for documentation such as a certificate of analysis (COA). This page counts what FDA has said publicly, so buyers can see how often the testing and supplier-COA rules come up. It says nothing about any supplier we list or might list.

What 21 CFR 111.75 covers, in FDA's words

FDA's letters explain the rule in their own words. Two quotes, each from a public FDA letter. The rule text is 21 CFR 111.75 on eCFR.

21 CFR 111.75(a)(2) does not allow firms to rely on a certificate of analysis to confirm the identity of a dietary ingredient. Rather, under 21 CFR 111.75(a)(1)(i), you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, prior to using a component...

On identity testing, from an FDA letter issued 5 June 2026. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mineral-biosciences-llc-724745-06052026

to rely on the supplier's certificate of analysis for components other than dietary ingredients you must meet the requirements of 21 CFR 111.75(a)(2)(ii).

On supplier COAs, from an FDA letter issued 15 May 2026. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/meta-labs-pharmaceuticals-llc-725130-05152026

[Editor check before publishing: re-open both pages and confirm each quote verbatim, including the ellipsis cut. Also link the eCFR text of 21 CFR 111.75, https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-111/subpart-E/section-111.75, after confirming it loads.]

The count, by year

2,595 non-tobacco letters scanned. Year is the letter issue date, not the date FDA posted the letter. 2026 is partial. 2021 is likely incomplete.

Table 1. Letters by year of issue date. 2,595 non-tobacco letters scanned. Footnote: 2026 is partial; 2021 is likely incomplete, see limits.
Year of issue dateNon-tobacco letters scannedLetters citing 21 CFR Part 111Of those, cite 21 CFR 111.75Cite 111.75(a)(1)Cite 111.75(a)(2)Cite 111.75(a)(2)(ii)Cite 111.75 and mention a COA
2021393110000
202242812103413
202338216126625
2024421841112
2025504960001
2026 (to 3 Nov)4671283223
Total2,59558411313614

12 of 16 Part 111 letters in 2023 cited 111.75, against 4 of 8 in 2024. Small counts, not a trend. 16 of the 58 (27.6%) cite 111.75(a)(1) or (a)(2).

Grouped bar chart of FDA warning letters citing the dietary supplement CGMP rule and, of those, the number citing section 111.75, by year from 2021 to 2026.Grouped bar chart of FDA warning letters citing the dietary supplement CGMP rule and, of those, the number citing section 111.75, by year from 2021 to 2026.Supplement CGMP letters and how many cite 111.75, by yearCite 21 CFR Part 111Of those, cite 21 CFR 111.75Hatched: 2026 partial yearNumber of letters0369121518112021likely incomplete12102022161220238420249620251282026 (to 3 Nov)partial year
FDA warning letters citing 21 CFR Part 111, and those that also cite 21 CFR 111.75, by letter issue date year. Source: CleanIngredients count of FDA's public warning letters table, data pulled 15 November 2026. 2026 is through 3 November.

Source: CleanIngredients, "FDA warning letters and supplement ingredient testing" (https://cleaningredients.co/research/fda-warning-letters-supplement-ingredient-testing), based on FDA's public warning letters table, data pulled 15 November 2026.

Download Chart 1 as PNG (1200 by 675 pixels).

Same numbers as the chart: letters citing 21 CFR Part 111, and letters citing 21 CFR 111.75, by issue-date year.
YearCite 21 CFR Part 111Of those, cite 21 CFR 111.75
2021 (likely incomplete)11
20221210
20231612
202484
202596
2026 (to 3 Nov) (partial year)128
Horizontal bar chart of which part of 21 CFR 111.75 is cited among 58 FDA warning letters that cite 21 CFR Part 111, all years from 2021 to 2026 combined. Categories overlap.Horizontal bar chart of which part of 21 CFR 111.75 is cited among 58 FDA warning letters that cite 21 CFR Part 111, all years from 2021 to 2026 combined. Categories overlap.Which part of 111.75 FDA cites, all years combinedOf 58 letters citing 21 CFR Part 111. Categories overlap. Share of 58 is labelled on each bar.Cite 111.75 at all41 (70.7%)Cite 111.75(a)(1) (identity test)13 (22.4%)Cite 111.75(a)(2) (other components, supplier COA)13 (22.4%)Cite 111.75(a)(2)(ii) (relying on a supplier COA)6 (10.3%)0153045Letters (scale 0 to 45)
Of 58 FDA warning letters citing 21 CFR Part 111 (4 Jan 2021 to 3 Nov 2026), how many cite each part of 111.75. Categories overlap. Source: CleanIngredients count, data pulled 15 November 2026.

Source: CleanIngredients, "FDA warning letters and supplement ingredient testing" (https://cleaningredients.co/research/fda-warning-letters-supplement-ingredient-testing), based on FDA's public warning letters table, data pulled 15 November 2026.

Download Chart 2 as PNG (1200 by 675 pixels).

Same numbers as the chart. Categories overlap, so they are not added together.
Part of 111.75LettersShare of 58
Cite 111.75 at all4170.7%
Cite 111.75(a)(1) (identity test)1322.4%
Cite 111.75(a)(2) (other components, supplier COA)1322.4%
Cite 111.75(a)(2)(ii) (relying on a supplier COA)610.3%

What the numbers do and do not show

What this means for a brand reviewing a supplier's documents

  1. Ask what the COA covers and whether it is per lot. Our methodology gives weight to a per-lot COA available without an NDA (see /methodology).
  2. Treat a COA as one input. In the FDA letters quoted above, a COA alone does not satisfy the identity-test requirement for a dietary ingredient; the brand's own identity test is the requirement FDA names.
  3. If you rely on supplier COAs for other components, FDA's letters point to 111.75(a)(2)(ii), which is about establishing that the supplier's COA is reliable (FDA's wording in the quoted letter: "confirmation of the results of the suppliers' tests or examinations").
  4. Run a COA through our free checker: /tools/certificate-of-analysis. It checks completeness of the document. It does not confirm the lab result is true.
  5. Our supplier verification guide: /information/how-do-we-verify-ingredient-suppliers.

[Have a qualified person confirm items 2 and 3 against the rule text before publishing. They restate FDA's quoted words; do not extend them.]

Download and cite

Method, step by step

  1. On 15 November 2026 we pulled FDA's warning letters table (3,807 rows, issue dates 4 Jan 2021 to 3 Nov 2026) from https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters.
  2. We removed rows from the Center for Tobacco Products and downloaded the full text of each remaining letter: 2,595 unique letters.
  3. We marked a letter as a supplement CGMP letter if its text cites 21 CFR Part 111: 58 letters.
  4. Among those, we searched the text for "111.75", "111.75(a)(1)", "111.75(a)(2)", "111.75(a)(2)(ii)", and "certificate of analysis" or "COA", and grouped by the letter's issue date year.
  5. The CSV lists every counted letter with its FDA URL so anyone can check a row.

Limits: FDA's table only; text matching; small counts; 2021 may be incomplete; 2026 is partial. We did not count inspections, Form 483s, recalls, or import refusals.

Limits

FAQ

What is 21 CFR 111.75?

It is a section of FDA's current good manufacturing practice rule for dietary supplements (21 CFR Part 111). It deals with determining whether specifications for components and finished product are met, including identity testing of dietary ingredients and conditions for relying on a supplier's certificate of analysis. Read the rule text on eCFR.

Does a certificate of analysis satisfy FDA's identity test requirement?

In the FDA letter quoted above, FDA wrote that 111.75(a)(2) "does not allow firms to rely on a certificate of analysis to confirm the identity of a dietary ingredient." Read the letter and the rule, and ask your regulatory advisor about your case.

How many FDA warning letters cite 111.75?

In our count, 41 of 58 supplement CGMP letters issued from 4 January 2021 to 3 November 2026. See the table for years.

Does this page say anything about China-based suppliers?

No. We did not filter by country.

Does CleanIngredients test suppliers or ingredients?

No. We do not independently test suppliers. Our transparency scores describe public documentation, not product safety. No confirmed offering is listed yet.

Can I reuse the chart or data?

Yes, with attribution to CleanIngredients and a link to this page. The underlying records are FDA's public letters.

Sources

Data pulled and change log

Data pulled 15 November 2026.

A later update should change the year table, the CSV, and the headline numbers together. Suggested cadence: once a quarter. No refresh is scheduled in this version.